Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Cambridge Cognition’s Full Digital Suite
Actinogen Enhances Phase 2b/3 Alzheimer’s Trial with Our Full Digital Suite Digital Measures that Matter Cambridge Cognition is excited to announce the expansion of its partnership with Actinogen Medical Limited for the Phase 2b/3 XanaMILA Alzheimer’s disease trial. Building on the successful integration of Cambridge Cognition’s full product suite including Cognitive Assessments (CANTAB), electronic Clinical […]
